Myelofibrosis News and Research

RSS

Anemia drugs linked with leukemic transformation in patients with primary myelofibrosis

Mayo Clinic researchers have reported the discovery of a link between erythropoiesis-stimulating agents (ESAs) and leukemic transformation (conversion to leukemia) of the blood disorder myelofibrosis.

10 Dec 2007

UIC receives $20 million NCI grant to research blood disorders

A $19.6 million National Cancer Institute grant has been awarded to the University of Illinois at Chicago College of Medicine to advance basic and clinical research for incurable blood disorders.

6 Sep 2006

MPD Foundation funds research for incurable blood disorders

The Myeloproliferative Disorders Foundation has awarded $750,000 to establish the MPD Research Alliance, a collaboration of the University of Illinois at Chicago, Harvard Medical School and Mayo Clinic to accelerate drug development for incurable, progressive bone marrow disorders.

11 Apr 2006

Three different leukemias are all caused by mutations that alter a specific enzyme controlling blood cell proliferation

Identifying the genetic malfunction that causes these disorders raises the hope that researchers may be able to devise a targeted therapy, just as they have done for chronic myelogenous leukemia (CML), which is presently treated with Gleevec. The three leukemias that share a common genetic cause are polycythemia vera (PV), essential thrombocythemia (ET) and myeloid metaplasia with myelofibrosis (MMM).

28 Mar 2005

Discovery of a single mutation responsible for a number of blood disorders

Myeloproliferative disorders form a range of haematological malignant diseases, with three main members: polycythaemia vera, essential thrombocythaemia, and idiopathic myelofi- brosis. The disorders are characterised by overactive production of blood cells and can lead to thrombosis, haemorrhage or acute myeloid leukaemia.

21 Mar 2005

Hydroxyurea plus aspirin best therapy in patients with essential thrombocythemia who are at high risk for vascular events

A new treatment for an incurable blood disorder proves a worse option for patients' health than an older treatment, according to a study to be presented today during the 46th Annual Meeting of the American Society of Hematology (ASH).

5 Dec 2004

Impaired cognitive and motor function following stem cell transplantation for severe blood disorders can improve

Patients who suffer a loss of cognitive and motor function as a result of stem cell transplantation for severe blood disorders are likely to see those functions return to previous levels after one year, according to a new study in the November 15, 2004, issue of Blood, the official journal of the American Society of Hematology.

8 Nov 2004

Thalidomide's role in fighting blood disorders, such as multiple myeloma

From the late 1950s to the end of 1961, thalidomide was a popular sedative and treatment for morning sickness until it was discovered to cause fetal malformations, which proved fatal within the first year of life in 40 percent of affected infants.

13 Jul 2004